INVO Fertility — Third Quarter 2026 Earnings Summary
Financial Performance:
- Total revenue increased 26% year-over-year to $2,222,656 from $1,757,094 in Q3 2025.
- Consolidated clinic revenue increased 28% year-over-year to $2,207,587 from $1,722,223.
- Product revenue decreased to $15,069 from $34,871, attributed to the elimination of sales to newly consolidated Indiana and Birmingham clinics.
- Net loss narrowed to $2.1 million ($2,149,920) from $3.4 million ($3,395,598) in the prior-year quarter.
- Loss from operations improved to $1.5 million ($1,477,360) from $1.6 million ($1,635,484).
- Clinic-Level Adjusted EBITDA was positive at $292,114, compared to $243,120 in Q3 2025, marking the seventh consecutive positive quarter.
- Consolidated Adjusted EBITDA was $(1.0) million, compared to $(0.9) million in Q3 2025.
- Cash on hand was $3.7 million ($3,695,770) as of September 30, 2026, compared to $2.1 million at December 31, 2025.
- Current liabilities decreased to $4.5 million ($4,457,529) from $10.3 million ($10,331,629) at year-end 2025.
- Net equity increased to $18.0 million ($18,005,253), or $15.09 per share, compared to $7.2 million at December 31, 2025.
- Total assets increased by $5.3 million to $25.5 million, while total liabilities reduced by $5.5 million to $7.5 million.
Guidance and Future Outlook:
- Management expressed confidence in the company's ability to execute growth plans and leverage infrastructure to expand the clinic network.
- The company anticipates continued opportunities for acquisitions as independent fertility practices seek to serve more patients while preserving local relationships.
- Future growth is expected to be driven by higher patient volumes, expanded services, and improved operating execution.
- Management plans to continue investing in people and infrastructure in advance of network expansion.
Business Segments and Product Lines:
- The Fertility Clinic Services Segment generated $2,207,587 in revenue, up from $1,722,223.
- Organic growth was observed at the Wisconsin and Atlanta clinics, with Wisconsin's entry into the Progyny network in Q1 2026 contributing to expanded patient access.
- The Indiana clinic, acquired in February 2026, and the Birmingham clinic, acquired in late June 2026, each contributed a full quarter of revenue.
- INVOcell, a proprietary medical device, continues to be sold and distributed to third-party owned and operated fertility clinics.
- The company operates four fertility clinics in the United States.
- New tools to reduce documentation and administrative time are being implemented to drive clinic-level efficiencies.
Market and Competitive Landscape:
- INVO attended the American Society for Reproductive Medicine Scientific Congress & Expo in October 2026, resulting in further expansion of potential acquisition opportunities.
- The company positions itself as a publicly traded alternative for investors to participate directly in the evolution of independent fertility practices.
Risks and Challenges:
- The Birmingham clinic acquisition transition resulted in an approximate $193,000 negative impact on Q3 Clinic-Level Adjusted EBITDA due to anticipated revenue disruption and increased costs associated with recruiting a new physician.
- Forward-looking statements involve risks and uncertainties, including factors that may cause actual results to differ materially from anticipated results, as detailed in SEC filings.
Management Commentary and Tone:
- CEO Steve Shum stated that revenue growth and positive clinic-level Adjusted EBITDA were achieved through a combination of organic growth and acquisitions.
- Management highlighted the strategic value of acquiring established, profitable clinics to increase scale and support corporate operating expenses.
- Shum noted the balance sheet has strengthened following the Wisconsin acquisition payment and reduction in current liabilities.
- The tone was optimistic regarding the team's capability to execute growth plans and the opportunities available in the market.
Other Key Points:
- INVO acquired the remaining 50% interest in the Birmingham clinic in June 2026 for a purchase price of $175,001.
- The number of common shares outstanding increased to 1,192,860 as of November 13, 2026, compared to 119,358 at December 31, 2025.
- A webcast to discuss results was held on November 16, 2026, at 11:00 a.m. Eastern Time.
- The company eliminated Series C-2 Preferred Stock (reducing from 3,004 shares to 0) and issued 400 shares of Series D Preferred Stock during the period.
- The company recognized a gain on remeasurement of $2,452,032 in the nine months ended September 30, 2026, which was not present in the prior-year period.
- Loss on debt extinguishment was $172,621 for the nine months ended September 30, 2026, compared to $2.1 million in the prior year.
- Company
- INVO FERTILITY INC
- Sector
- Healthcare
- Industry
- Medical Devices